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Abstract: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are significant 
public health concerns around the world. Despite decreasing incidence, there is still a significant 
disease burden, especially in developing nations. This review provides background on the 
history of ARF, its pathology and treatment, and the current reported worldwide incidence of 
ARF and prevalence of RHD.
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Introduction
Acute rheumatic fever (ARF) is a postinfectious, nonsuppurative sequela of pharyngeal 
infection with Streptococcus pyogenes, or Group A β hemolytic Streptococcus 
(GABHS). Of the associated symptoms, only damage to the valve tissue within the 
heart, or rheumatic heart disease (RHD), can become a chronic condition leading to 
congestive heart failure, strokes, endocarditis, and death. While the incidence and 
prevalence of ARF and RHD have been decreasing in developed nations since the 
early 1900s, they continue to be major causes of morbidity and mortality among young 
people in developing nations. It is estimated that there are over 15 million cases of 
RHD worldwide, with 282,000 new cases and 233,000 deaths annually.1
More recent data using echocardiography to screen for RHD in developing nations 
have lead to a marked increase in the recognized prevalence in these regions.2–6 
With these new data, there has been an increased awareness and interest in ARF and 
RHD, which stimulated this review of the literature to provide information on the 
pathogenesis, diagnosis, and treatment for ARF and RHD, and an updated estimate 
of the worldwide incidence and prevalence.
Background
Although physicians in Europe had been describing clinical components of ARF since 
the 1500s, it was William Charles Wells’ seminal publication in 1812 that definitively 
linked ARF with carditis.7 The entire clinical spectrum of ARF (from tonsillitis to 
carditis) was first described by Cheadle in 1889.8 The infectious etiology of ARF was 
long suspected, especially given the seasonal variation in outbreaks, and in 1900 Poynton 
and Paine described a diplococcus isolated from patients with ARF, which they impli-
cated as a causal organism for the disease.9 Micrococcus (or Streptococcus) rheumaticus 
was isolated from a patient with ARF in 1904, and was noted to be “indistinguishable 
from strains of Streptococcus pyogenes”.10 Into the 1930s, theories implicating viruses 
as causal agents for ARF surfaced,11 and are still being investigated today.12,13Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Methods
An extensive literature search for any articles about “acute 
rheumatic fever” or “rheumatic heart disease” was performed 
in August 2010 using PubMed. Articles reporting data of 
the incidence of ARF or prevalence of RHD were reviewed. 
In order to maximize the available information, non-English 
language articles were included if it was possible to obtain an 
English translation of either the abstract or the entire article.
To generate trends of ARF incidence and RHD prevalence 
over time, data from various countries were clustered by 
World Health Organization (WHO) region – Africa, the 
Americas, Southeast Asia, Europe, Eastern Mediterranean, 
and Western Pacific. Data reported from any countries within 
a WHO region for a given year were averaged together 
to provide a value for that year. These data were plotted for 
the time period 1970 to 2009, and trend lines were calculated 
with quadratic regression for each WHO region and are 
reported in the graphs. Regional incidence and prevalence 
estimates were not weighted by the underlying population.
The last major WHO report on the worldwide prevalence 
of ARF and RHD reported data through 1990.14 This year 
was used as a cutoff to create 2 eras: 1970 through 1990, 
and 1991 through the present. ARF incidence and RHD 
prevalence rates for each reporting country during these eras 
were graded and plotted on a world map to show the changes 
in disease burden and geographic location with time in more 
detail than the trend plots.
Jones criteria for each of the WHO regions were compared 
using one way ANOVA with post-hoc analysis to identify 
significant differences in criteria between regions.
Diagnosis
The diagnostic criteria for ARF were first developed by Jones 
in 194415 and have since been modified in 1965,16 1984,17 
1992,18 and 2002.19 The criteria are divided into Major and 
Minor criteria (Table 1). Diagnosis is made by the presence of 
either 2 Major or 1 Major and 2 Minor criteria, plus evidence 
of recent streptococcal infection, either by a pharyngeal swab 
culture positive for GABHS, positive rapid GABHS   antigen 
test or rising serologic antibody titers (antistreptolysin 
O [ASO], DNAse B, or streptokinase).18
The Major criteria are migratory polyarthritis, carditis, 
Sydenham chorea, erythema marginatum, and subcutaneous 
nodules. Polyarthitis is redness, swelling, and intense pain 
of multiple, usually large, joints that can change from one 
location to another as the disease progresses. Carditis is 
typically valvulitis and has traditionally been diagnosed 
by a new murmur suggestive of valvar regurgitation, but 
echocardiography has been used more in recent years to aid 
in the diagnosis (see below). There may be myocarditis or 
pericarditis in addition to the valvulitis. Sydenham chorea, 
or St. Vitus’ dance, is rapid, uncontrolled movements of the 
trunk or extremities. There can also be worsening school 
performance, behavioral changes, and emotional lability. 
Erythema marginatum is a transient rash with central pallor 
and red, serpiginous (snake-like) borders found on the trunk 
and extremities. Subcutaneous nodules are painless, flesh-
colored bumps, usually found on the extensor surfaces of 
the arms and legs.18
The Minor criteria are arthralgias, fever, elevated acute-
phase reactants, and first degree heart block. Arthralgia is 
pain, often in multiple joints, without associated redness 
or swelling. Of note, a patient can have either arthritis or 
arthralgia as a Jones criterion, but not both. Fever, usually at 
least 39°C, is common in early ARF. Acute-phase reactants 
are nonspecific laboratory markers of inflammation in the 
body. The typical ones measured are erythrocyte sedimenta-
tion rate (ESR) and C-reactive protein (CRP), both of which 
are expected to be elevated during an episode of ARF. These 
markers can also be followed as signs of resolution of ARF. 
First degree heart block is diagnosed by prolongation of the 
PR interval on electrocardiogram (Figure 1). Having first 
degree heart block does not predict whether a patient will 
develop RHD.18
There has been controversy over the use of Doppler 
echocardiography in the diagnosis of ARF.19,20 Many argue 
Table 1 Major and Minor Jones criteria for the diagnosis of acute 
rheumatic fever18
Major criteria Minor criteria
Migratory polyarthritis Arthralgia
Carditis Fever
Erythema marginatum First degree heart block
Syndenham chorea Elevated inflammatory markers (ESR, CRP)
Subcutaneous nodules
Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
Figure 1 Electrocardiogram demonstrating first-degree heart block in a patient 
with acute rheumatic fever. The PR interval is noted by the arrows, and is markedly 
prolonged at 300 milliseconds (normal for an adult is less than 200 milliseconds).Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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that echocardiography can help to diagnosis subclinical RHD, 
especially among high-risk populations.21–24 However, since 
it is not known how much valvar regurgitation is “normal”, 
there is concern for overdiagnosis of carditis by relying on 
Doppler echocardiography.19 The current American Heart 
Association guidelines recommend the use of Doppler 
echocardiography as a supplement to diagnosis, but evidence 
of valvar regurgitation should not be used as a Major or 
Minor criterion.
Pathophysiology
Even though ARF has been recognized as a disease entity for 
at least 150 years, a clear understanding of the pathophysi-
ology still eludes modern physicians. The role of GABHS 
infection as an initial event is clear, and has been supported 
by outbreaks of ARF following outbreaks of pharyngitis, 
as well as rising antistreptococcal antibodies in patients 
with ARF.25 ARF is believed to be an autoimmune reaction to 
GABHS infection. Genetically determined host susceptibil-
ity has long been presumed, especially given the tendency 
for outbreaks to occur within families and the relatively 
few cases of ARF that develop given the high prevalence 
of GABHS pharyngitis and pharyngeal carriage.26 Many 
studies have investigated the role of HLA alleles, which 
are located on chromosome 6, in ARF susceptibility, and 
while there have been no universal associations, HLA-
DR7 has been the most frequently associated with ARF 
and RHD.27–45
While the exact mechanism by which certain genes 
can confer an increased susceptibility to ARF has not 
been delineated, there are theories about the roles played. 
HLA molecules process antigens within a host cell and 
present them on the cell surface to T cells, which can then 
attack the antigen or activate B cells to produce antibodies 
to the antigen. If the HLA molecules present antigens that 
resemble both Streptococcus and human tissues, then host 
cells can be attacked. This is called molecular mimicry and 
will be discussed more below. Another protein that has been 
associated with ARF and RHD is the inflammatory cytokine, 
tumor necrosis factor-α (TNF-α), which is also located 
on chromosome 6 near the HLA alleles. TNF-α may be 
upregulated in patients with increased ARF susceptibility, 
leading to an increased inflammatory response in these 
patients, and subsequent development of ARF.30 A third fac-
tor, mannose-binding lectin (MBL), binds to various sugar 
molecules on the cell surface and helps to mark foreign cells 
for immune cells to eliminate. RHD patients with mitral 
valve damage have been found to have high levels of MBL 
in their blood, while those with aortic valve damage have 
low levels.30
The theory of cross-reaction between GABHS and heart 
tissue has been explored for at least 60 years. Cavelti first 
identified anticardiac autoantibodies in ARF in 1945, and 
subsequently demonstrated that anticardiac and   antiskeletal 
muscle antibodies were produced in rats, but only in the 
presence of killed streptococci.46,47 These antibodies could 
subsequently react to, and damage, host tissue without the 
continued need for streptococci to be present.48 In 1962, 
Kaplan and colleagues demonstrated a cross-reactivity 
between human heart tissue and GABHS49 and later 
anticardiac antibodies in patients with ARF.50 Further 
study has led to the identification of the M-protein on the 
GABHS cell membrane as the likely antigen for inducing 
the production of antibodies that cross-react with human 
heart tissue.
The cross-reactivity is believed to occur through molecular 
mimicry, where all or part of a foreign antigen resembles 
at least some portion of host tissue. In ARF and RHD, the 
foreign antigen is the M-protein and it cross reacts with 
cardiac myosin, which induces T-cell mediated attack of the 
heart tissue and valves. Once valve tissue is damaged and 
inflamed, proteins that are normally intracellular can become 
exposed to invading immune cells and lead to the develop-
ment of more autoantibodies directed at different component 
proteins of valve tissue.30 This leads to further inflammation 
and scarring of heart valve tissue and chronic RHD. All four 
heart valves can be involved in rheumatic carditis; however 
there is a marked predominance of mitral valve involve-
ment. This has recently been associated with higher levels 
of MBL,30 but is not clear why more MBL leads to damage 
of the mitral valve. Since all heart valves develop from the 
same tissue, they should be equally susceptible to attack from 
an autoantibody.51
Once heart valves have been damaged, they do not 
function properly, and blood is allowed to leak backward, 
or regurgitate. In severe cases, this can cause acute congestive 
heart failure, which can be the presenting symptom of ARF. 
Figure 2a shows normal cardiac anatomy and Figures 2b 
and 2c show echocardiograms demonstrating a thickened, 
regurgitant mitral valve. In addition to the usual treatment 
for ARF, these patients require medical   management for 
their heart failure. Patients that recover from the initial 
  rheumatic carditis are likely to have permanent valve   damage, 
and over time the affected valves can become stenotic in 
addition to regurgitant. Severe valve stenosis or   regurgitation 
can eventually warrant surgical repair or replacement of Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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the affected heart valves. A recent review of 361 cardiac 
  surgeries for rheumatic disease (RHD, neonatal lupus, 
systemic lupus, Kawasaki disease, or juvenile rheumatoid 
arthritis) among 261 North American patients from 1985 to 
2005 found that 55% of the surgeries were for RHD (160 
patients, 200 procedures) with 3 in-hospital deaths.53 In   
various series of patients with endocarditis, RHD was the 
underlying cause in 15% to 76.6% of cases, with mortality 
from endocarditis ranging from 29% to 36%.54–57 The cost of 
surgical intervention for RHD is approximately US$25,000, 
which is enough to fund 1 year of an RHD screening program 
in a small developing nation.58 Early detection of ARF and 
RHD through screening programs can reduce the morbid-
ity of chronic RHD and surgeries for heart valve repair or 
replacement.
There appears to be molecular mimicry involved in the 
development of Syndeham chorea as well. Numerous studies 
have provided evidence for anti-neuronal antibodies to the 
basal ganglia in patients with Sydenham chorea.59 Kirvan and 
colleagues recently found a carbohydrate   component of the 
streptococcal cell wall that cross-reacts with gangliosides in 
the cell membrane of neurons in the basal ganglia. Not only 
does this cause inflammation and damage neurons, but since 
gangliosides are involved in cell signaling,   neuronal path-
ways can be disrupted as well.60 One function of the basal 
ganglia is inhibition of motor impulses. Damage to this 
area can explain the unusual movements associated with   
Sydenham chorea.
Investigators have used MRI to examine the brains of 
patients with Sydenham chorea to determine the   etiology 
of the movement, speech and behavioral issues. One of the 
  earliest reports of brain MRI findings in acute   Sydenham 
chorea demonstrated increased signal intensity in the 
caudate nucleus, a component of the basal ganglia, with 
  associated edema and shifting of brain matter.61 This 
appeared to   correlate with pathologic findings seen in 
  varying case series which show blood vessel inflammation, 
occlusion and necrosis in early disease, and degenerative 
changes in   recurrent chorea.61,62 Subsequent case series 
have   demonstrated acute changes in the caudate nucleus 
(some of which progressed to cystic changes on subsequent 
studies)63 and others with lesions in the subcortical white 
matter, which may be the cause of speech and behavioral 
symptoms.64
Figure 2 a) Artist rendition of normal left heart anatomy, demonstrating the left atrium connected to the left ventricle via a mitral valve.52 b) Two-dimensional echocardiogram 
of the left heart, demonstrating a thickened anterior leaflet of the mitral valve. c) Two-dimensional echocardiogram with color Doppler, demonstrating moderate-to-severe 
mitral valve regurgitation (blue jet).Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Treatment
Primary prevention
There are several approaches to reduce the impact of ARF. 
The first line is primary prevention through the recognition of 
GABHS pharyngitis and treatment with appropriate antibiotics. 
Antibiotic therapy initiated within 9 days of onset of phar-
yngitis is effective in preventing ARF.65,66 Oral penicillin V 
is still the first line treatment in patients whom compliance 
can be expected, and there has never been documentation of 
GABHS isolates that are resistant to penicillin. For patients in 
whom compliance with an oral regimen is a problem, a single 
intramuscular dose of benzathine penicillin G (BPG) can be 
given at the time of GABHS pharyngitis diagnosis. Patients 
that have a hypersensitivity to penicillin may be treated with 
a first-generation cephalosporin, but as many as 5% may 
also be allergic to cephalosporins. Macrolides, including 
erythromycin, clarithromycin, and azithromycin, are another 
alternative, although there have been GABHS strains 
that demonstrate macrolide resistance. Fluoroquinolones, 
  tetracyclines, and sulfonamides are not recommended to treat 
GABHS pharyngitis.65,66 Full details of antibiotic treatments 
for GABHS pharyngitis are shown in Table 2.
Another intriguing area of research for the past 40 years 
in ARF prevention is GABHS vaccine development. While 
there are many potential vaccine candidates, the extracel-
lular M-protein on the surface of GABHS cells has become 
the primary target, and there are currently 4 vaccines 
in development targeting the M-protein.67,68 Part of the 
complexity in vaccine development is the high   variability 
Table 2 Antibiotic regimens for treatment of group A streptococcal 
pharyngeal infections. 
Antibiotic Dose Duration
Penicillin v 250 mg by mouth 2 to 3  
times daily (#27 kg) or 
500 mg by mouth 2 to 3  
times daily (.27 kg)
10 days
Benzathine  
penicillin G
600,000 units intramuscular  
(#27 kg) or 
1,200,000 units intramuscular  
(.27 kg)
Once
Amoxicillin 50 mg/kg by mouth daily 10 days
Cephalosporina  
(first generation)
Drug-dependent 10 days
Clindamycina 20 mg/kg/day divided in  
3 doses by mouth
10 days
Clarithromycina 15 mg/kg/day divided  
in 2 doses by mouth
10 days
Azithromycina 12 mg/kg by mouth daily 5 days
Notes: ain penicillin-allergic patients. Note, up to 5% of patients allergic to penicillin 
may also be allergic to cephalosporins.
Source: American Heart Association, inc.66
Figure 3 Schematic drawing of the M-protein structure with the conserved (blue), 
variable (red), and hypervariable (green) regions. Note that the conserved region is 
closest to the cell membrane.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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of the M-proteins, with over 150 M-types identified. 
  Figure 3 shows a schematic of the structure of the M-protein, 
with conserved, variable, and hypervariable regions. The 
hypervariable region is exposed to the host immune sys-
tem and is the portion that distinguishes each M subtype. 
For the 26-valent GABHS vaccine, the decision about which 
M-types to include was based on the United States Centers 
for Disease Control’s Active Bacterial Core Surveillance of 
the Emerging Infections Program Network. The 26 chosen 
strains were those associated with pharyngitis, invasive 
disease, and ARF, so-called “rheumatogenic” strains.69 It is 
important to note that these strains are based only on data 
from the United States, which will be discussed more later. 
The other three M-protein-based vaccines in development 
target the conserved region of the M-protein, and are likely 
to provide protection against a wider range of M-types.68 
Since ARF is thought to be due to an autoimmune response 
to the M-protein and molecular mimicry of the heart valve 
tissue, there is concern that vaccination could actually cause 
ARF. This was seen in an early M-protein vaccine trial in 
the 1960s where all patients receiving the vaccine developed 
antistreptococcal antibodies, but 3 of 21 also developed ARF, 
compared to 5 of 447 controls.70,71
Acute treatment
Salicylate therapy for the symptoms of ARF was first 
attempted successfully by Maclagan in 1876.72,73 Since 
then, a variety of treatments have also been attempted 
for ARF, including irradiation of the heart,74 administra-
tion of ascorbic acid and orange juice,75 or heparin,76 and 
prolonged confinement to a hyperoxic chamber.77 While 
aspirin has remained the mainstay of ARF therapy, the exact 
action of effect is unclear, but seems to be related to the 
anti-inflammatory properties. This has prompted the study 
of other anti-inflammatory medications.
A large multi-center study in the United States and 
United Kingdom in 1955 compared the efficacy of aspirin, 
cortisone, and adrenocorticotropic hormone for the acute 
treatment of the symptoms of ARF. They found that there 
was no difference in final outcomes; the hormonal treatments 
caused more rapid resolution of some symptoms, but at the 
cost of higher recurrence rates.78 A more recent meta-analysis 
confirmed these results and found no significant reduction in 
the development of RHD with corticosteroids compared to 
aspirin.79 Given the higher likelihood of side effects from ste-
roid treatment, aspirin has remained the first line treatment for 
uncomplicated ARF.21 Treatment with aspirin usually causes 
marked improvement in the joint manifestations of ARF within 
24 to 48 hours, which can help distinguish ARF from other 
arthritides which do not resolve as quickly. For those who can-
not tolerate aspirin, naproxen has been used as an alternative 
anti-inflammatory agent.80,81 Some groups do recommend the 
use of corticosteroids for carditis in patients who are in severe 
heart failure.21,22 Anti-inflammatory medications are given until 
the inflammatory markers normalize, usually 4 to 6 weeks.
There have been studies showing decreased   severity 
and duration of chorea with prednisone therapy.82 Paz and 
colleagues82 performed a placebo-controlled study on a 
group of 37 children with Sydenham chorea, treated 22 
with prednisone, and found a quicker resolution of chorea 
symptoms in the treatment group. Given the inflammatory 
changes seen on pathologic specimens,61,62 corticosteroid 
treatment for chorea is a logical choice. However, the progres-
sion to degenerative changes seen in recurrent chorea makes 
corticosteroids less likely to be of any benefit in this group.
Secondary prophylaxis
Those patients who develop ARF are at high risk to develop 
subsequent attacks when infected with GABHS, and so 
this population is best treated with secondary antibiotic 
  prophylaxis after their initial attack (Table 3). Patients who 
have recurrences of ARF are at risk to develop carditis, if they 
had not already, or worsen existing valve damage. Antibiotic 
choices are similar to those for GABHS pharyngitis. Sec-
ondary antibiotic prophylaxis is only effective when there is 
high compliance,66,83 so many healthcare providers prescribe 
intramuscular BPG every 4 weeks to ensure adequate serum 
penicillin levels. Studies in areas highly endemic for ARF 
have found that BPG dosed every 3 weeks provides better 
prevention of recurrent ARF.84 If patients are compliant with 
oral regimens, these can be equally effective.
Secondary antibiotic prophylaxis should be given to 
individuals most at risk for GABHS pharyngeal infections. 
These include children, people living in crowded conditions 
Table 3 Antibiotic regimen for secondary prophylaxis of acute 
rheumatic fever. 
Antibiotic Dose
Benzathine penicillin G 600,000 units intramuscular (#27 kg) or 
1,200,000 units intramuscular (.27 kg) 
Every 4 weeks (3 weeks in high-risk 
areas/populations)
Penicillin v 250 mg by mouth twice daily 
Sulfadiazine 0.5 g by mouth daily (#27 kg) or 
1 g by mouth daily (.27 kg)
Macrolidea Drug-dependent
Notes: ain penicillin-allergic patients. Note, up to 5% of patients allergic to penicillin 
may also be allergic to cephalosporins. 
Source: American Heart Association, inc.66Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Table 4 Reported incidence of acute rheumatic fever (ARF) (per 
100,000 persons) from 1930 through 1970
Years Country Subgroup ARF (/100,000)
1930–1964 Sweden85 25 → 1.3
1935–1949 United States  
(Minnesota)86
35–65
1948–1953 England  
(Bristol/Sheffield)87
25.5–55
1949–1961 United States  
(Colorado)88
12–14
1950 Costa Rica89 120
1952 Peru90 27
1952–1957 Sri Lanka91 112
1960–1964 United States  
(Maryland)92
15.6
1960–1964 United States  
(Utah)93
4.7–6.4
1963–1965 United States  
(New York)94
African  
Americans
47
1963–1965 United States  
(New York)94
Puerto Ricans 78
1963–1965 United States  
(New York)94
whites 23
1963–1969 United States  
(Tennessee)95
African  
Americans
44.4
1963–1969 United States  
(Tennessee)95
whites 21.9
1966 Denmark85 1.5
1965–1966 Fiji96 Fijians 13
1965–1966 Fiji96 indians 140
1970 United States  
(Arizona)97
Papago tribe 92
Table 5 Reported prevalence of rheumatic heart disease (RHD) 
(per 1000 persons) from 1935 through 1970
Years Country RHD (/1000)
1935–1964 United States (Minnesota)86 20.6 → 12
1949–1951 United States (Colorado)88 6.7
1958–1961 Japan98 4.6 → 2.1
1961 USSR99 10–30
1964–1965 Pakistan (Karachi)100 1.8
1966 india (Chandigarh)101 1.8
1970 Taiwan (Taipei)102 1.4
1970 Uruguay103 1
(military recruits, college students), parents, teachers, and 
healthcare workers. The American Heart Association guide-
lines state that individuals who have had ARF without carditis 
should be treated until the age of 21 years or 5 years after their 
last attack, whichever is longer. Those with RHD should be 
treated until 40 years of age or 10 years after their last attack, 
whichever is longer. The most important component of these 
guidelines is the need to assess each patient’s clinical situa-
tion to determine if they have continued high-risk exposure 
to GABHS which could warrant lifelong prophylaxis. It is 
also recommended to continue prophylaxis after heart valve 
replacement surgery, as any of the four cardiac valves can 
be affected by ARF.65,66
Results
Of the 164 articles reviewed for ARF incidence and RHD 
prevalence data, 85 utilized population-based screening, 
national health registries, prospective disease surveillance, 
surgical series, or autopsy series. Seventy-nine studies were 
retrospective reviews of hospital admissions or discharges 
for ARF or RHD, data from specialty referral clinics, or 
studies from which the data collection methods could not 
be determined. In order to maximize the available data, all 
studies were included.
The literature review revealed data on the incidence 
and/or prevalence of ARF and RHD in 100 countries around 
the world. Tables 4 and 5 show the reported incidence of ARF 
and prevalence of RHD for the era before 1970. Figures 4 
through 7 present the incidence of ARF and prevalence of 
RHD during the 1970 to 1990 and 1991 to present eras.
Figures 8 and 9 are graphs of the trend of ARF incidence 
and RHD prevalence for each WHO Region. The reported 
incidence of ARF is decreasing in all WHO Regions except 
for the Americas where it appears to be increasing slightly 
and the Western Pacific, where it appears to be steadily 
increasing. The reported prevalence of RHD is increasing 
in all regions except for Europe, where it appears to be 
decreasing.
Table 6 shows the percentages of patients with the 
Major and Minor criteria for each WHO region and for 
all reported studies combined. There was a slight male 
predominance in all ARF cases, and the only significant 
difference between regions was a higher male predomi-
nance in Southeast Asia compared to the Western Pacific 
(P = 0.049).   Overall, carditis occurred in 60% of cases, but 
the Americas had significantly fewer cases than the Western 
Pacific or Southeast Asia (P = 0.005 and 0.019, respectively). 
Arthritis also occurred in 60% of all cases and Southeast 
Asia had significantly fewer cases than the Americas, 
Europe and the Eastern Mediterranean (P = 0.002, 0.011 
and 0.013, respectively). There were more cases of ery-
thema marginatum in the Americas than in Southeast Asia 
(P = 0.015), and in the Western Pacific than in both the 
Eastern Mediterranean and Southeast Asia (P = 0.015 and 
0.003, respectively). The Americas also had more cases of 
chorea than the Eastern Mediterranean (P = 0.025). Fever 
and an elevated ESR were reported less often in Africa 
than any of the other regions, and ESR elevation was less 
in Southeast Asia than in the Eastern Mediterranean and 
Western Pacific (P = 0.019 and 0.041, respectively). Elevated Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Figure 4 Map showing reported worldwide incidence of ARF from 1970 through 1990.86,97,104-156 (1) Barbados,104,105 (2) Fiji,112 (3) French Antilles,113 (4) French Polynesia,112 
(5) Federated States of Micronesia,114 (6) israel,120 (7) Kuwait,123-125 (8) New Caledonia,112 (9) Northern Mariana islands,133 (10) Samoa,112 (11) Tonga,112,136 (12) Trinidad,137 
(13) Alabama,140 (14) Arizona,97 (15) California,141,142 (16) Florida,143 (17) Hawaii,144-146 (18) Minnesota,86 (19) Mississippi,147 (20) Navajo Reservation,148 (21) Ohio,149,150 (22) Rhode 
island, 151 (23) Tennessee,152 (24)Utah,93 (25) virginia,153 (26) west virginia,154,155 (27) wyoming.97
ARF
(/100,000 persons)
<5
5–20
20–40
40–100
>100
Figure 5 Map showing reported worldwide incidence of ARF from 1991 through present.40, 108, 111, 115, 120, 139, 156-200 (1) American Samoa,159,192 (2) Fiji,169-171 (3) Grenada,175 
(4)  israel,120,178  (5)  Jordan,179  (6)  Kosrae,  Federated  States  of  Micronesia,181  (7)  Lebanon,182  (8)  New  Caledonia,185  (9)  Northern  Mariana  islands,133  (10)  Qatar,190 
(11) west virginia.199
ASO titer was more common in the Americas, Europe, 
Eastern Mediterranean, and Western Pacific than in Africa 
(P = 0.002, 0.022, ,0.001, and 0.036, respectively), and in 
the Americas and Eastern Mediterranean than in Southeast 
Asia (P = 0.026 and 0.005, respectively). Regional ARF 
recurrence rates ranged from 8% to 34%, with Europe 
having significantly fewer recurrences than the Americas, 
Eastern Mediterranean, Western Pacific, and Southeast Asia 
(P = 0.013, 0.004, 0.025, and 0.001, respectively); Africa had 
fewer recurrences than Southeast Asia (P = 0.049). There 
was no difference in subcutaneous nodules, arthralgia, or 
first-degree heart block between all 6 regions. There were not 
enough data available to compare differences in Major and 
Minor criteria between the two eras to evaluate for changes 
in presenting Jones criteria over time.
The reported M-types are presented in Figure 10, showing 
M-types from developing nations (Figure 10a), developed 
nations (Figure 10b), and both combined (Figure 10c). For Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Figure 6 Map showing reported worldwide prevalence of RHD from 1970 through 1990.14,21,86,90,99,102-104,111,112,118,128,132,136,201-216 (1) Barbados,104 (2) Cook islands,21 (3) El Salvador,202 
(4) Fiji,112 (5) French Polynesia,112 (6) Jamaica,202 (7) Puerto Rico,103 (8) Samoa,112 (9) Tonga,112,136 (10) Minnesota.86
RHD
(/1,000 persons)
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 1–2
 2–4
 4–10
>10
Figure 7 Map showing reported worldwide prevalence of RHD from 1991 through present.2-6,21,111,160,168,169,176,177,189,191,192,197,217-240 (1) Fiji,169,228 (2) Samoa,192 (3) Tonga.3
comparison, in Figure 10 the 26 M-types present in the 
GABHS vaccine currently being tested are noted by an 
asterisk.69,241
Discussion
This is the most comprehensive review of the incidence and 
prevalence of ARF and RHD in the English literature to date. 
The inherent limitations to the methods of many reviewed 
studies, especially those presenting data from specialty refer-
ral clinics or hospital admissions, do not allow calculation 
of exact incidence rates. However, these data make clear 
that ARF and RHD still exist in significant numbers around 
the world, which is a disappointment from a public health 
standpoint.
As might be expected, practice patterns for ARF diag-
nosis vary across countries. In Africa, where public health 
resources are limited, only 50% of patients diagnosed with 
ARF had laboratory evidence of a recent streptococcal 
infection demonstrated by an elevated or rising ASO titer. 
All patients diagnosed with ARF were treated accordingly. Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Figure 8 Trends of acute rheumatic fever incidence per 100,000 persons for each wHO region, A) The Americas, B) Europe, C) Africa, D) Eastern Mediterranean, 
E) Western Pacific, and F) Southeast Asia. Points represent reported incidence from the literature.
Similar practice patterns can be noted in the other poorer 
WHO regions – Western Pacific and Southeast Asia. Because 
of the endemic nature of ARF in these regions and the marked 
impact of progression to chronic RHD, it is reasonable to be 
aggressive with ARF diagnosis and treatment.
The decrease in ARF incidence is consistent with prior 
studies that have shown the incidence to be decreasing 
since the early 20th century. This trend has been attrib-
uted to improved living conditions, the use of antibiotics 
for GABHS pharyngitis and possibly shifting GABHS 
serotypes. The upward trend in our calculated incidence 
of ARF in the Americas is likely due to the high incidence 
reported from Mexico in 1995, which is easily seen as 
an outlier in the maps in Figures 4 and 6. The apparent 
increase in incidence in the Western Pacific is more likely 
improved recognition and reporting of ARF in this region. 
The reported incidence is only now approaching an average 
100/100,000 people, which is likely what the true incidence 
has been. One possibility for the high incidence of ARF in 
the Western Pacific region is that many of the countries are 
small island nations. These countries have small, relatively 
isolated populations, and so even a small outbreak of ARF 
can be calculated as a high incidence level, given relatively 
small denominators.133,161
The prevalence of RHD appears to be increasing world-
wide. Given that the incidence of ARF has been decreas-
ing in most regions, it is not likely due to increases in the 
disease. Major advances in medical and surgical treatments 
for RHD have led to increased survival, which has con-
tributed to an increased prevalence of RHD. RHD is also 
more rigorously sought out, and newer studies relying on 
echocardiography to enhance the diagnosis of RHD have 
shown that subclinical carditis exists at rates up to 10 times 
higher than that diagnosed by examination alone.2–6 Rec-
ognition of subclinical carditis will identify those children 
who would benefit from secondary antibiotic prophylaxis 
and hopefully prevent the progression to clinically signifi-
cant RHD.   Population-wide echocardiographic screenings 
may be subject to length time bias or pseudodisease, and 
the children diagnosed are likely to be among the majority 
of ARF patients in whom carditis resolves within a year 
of initial attack. Nevertheless, their increased likelihood Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Figure 9 Trends of rheumatic heart disease prevalence per 1000 persons for each wHO region, A) The Americas, B) Europe, C) Africa, D) Eastern Mediterranean, 
E) Western Pacific, and F) Southeast Asia. Points represent reported prevalence from the literature.
Table 6 Percentage of major and minor criteria by wHO region and for all reported studies
WHO region Males Recurrences Major criteria Minor criteria
Carditis Arthritis EM Chorea Nodules Arthralgia Fever ↑ PR ESR ASO
The Americas 54.7% 22.0% 52.8% 64.4% 7.8% 15.3% 3.8% 40.9% 63.9% 23.3% 84.2% 79.4%
Europe 54.7% 7.9% 62.0% 65.7% 5.5% 12.3% 8.0% 43.1% 68.9% 26.3% 81.5% 78.3%
Africa 50.1% 17.9% 63.3% 48.9% 1.7% 8.8% 4.8% 55.5% 35.4% 22.7% 52.9% 48.7%
Eastern  
Mediterranean 
54.4% 27.9% 60.3% 63.5% 2.8% 8.0% 1.6% 34.5% 74.8% 20.3% 90.5% 86.9%
Western Pacific 48.2% 22.6% 67.5% 54.3% 11.0% 11.7% 1.5% 35.1% 68.4% 24.7% 91.0% 72.3%
Southeast Asia 57.4% 33.9% 66.0% 46.0% 0.8% 15.4% 4.4% 45.5% 71.3% 28.9% 71.9% 60.9%
All 53.7% 21.9% 59.5% 59.3% 5.9% 12.9% 3.7% 40.7% 65.6% 24.1% 81.4% 75.3%
Note: Proportions are restricted to acute rheumatic fever patients.
Abbreviations: EM, erythema marginatum; ↑ PR, prolonged PR interval on ECG; ESR, increased erythrocyte sedimentation rate; ASO, elevated antistreptolysin O titer.
of recurrent ARF, and worsening of prior valvar lesions, 
makes it appropriate that these children receive secondary 
antibiotic prophylaxis.
Given the relative ease and low cost of GABHS phar-
yngitis treatment to prevent ARF occurrence, there is little 
excuse for hundreds of thousands of new cases of ARF 
annually. Authors cite varying reasons such as patients 
not seeking care for pharyngitis, poor compliance with 
antimicrobial regimens, or even ARF without a clinically 
apparent preceding sore throat as missed opportunities to 
prevent ARF.242,243 A recent meta-analysis of the treatment 
of GABHS pharyngitis to prevent ARF concluded that 
there would be an approximately 60% reduction in cases of 
ARF if pharyngitis was appropriately treated, especially in 
endemic areas.243 These are similar to Gordis’ findings from 
the 1970s in Baltimore.242 Implementing systematic sur-Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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veillance and treatment of GABHS pharyngitis, particularly 
through school-based programs, is crucial to the control and 
prevention of ARF.244 In highly endemic areas, some providers 
choose to empirically treat patients in the 5- to 15-year age 
range with fever and complaints of sore throat, even with-
out any laboratory evidence of GABHS infection (M.D.S., 
personal communication). With the low risk of side effects 
or induction of antibiotic resistance with penicillin therapy 
compared with the significant risk associated with ARF, this 
strategy may be justified.
The likelihood of genetic susceptibility to ARF is high, 
given the increased occurrence of ARF among families 
and monozygotic twins.28,245 The HLA-D8/17 and HLA-
DR7 types are the most represented in the literature among 
patients with ARF and RHD, but there are still many other 
HLA alleles that are identified in only single studies.27–45,245 
The variability in reported HLA alleles associated with 
ARF and RHD could be due to genetic differences in the 
populations studied or differences in local streptococcal 
strains. Given the current state of the literature, it is hard 
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Figure 10 Number of reported occurrences of each streptococcal M-type in A) developing nations, B) developed nations, and C) both combined.
Note: *denotes M-types contained in 26-valent GABHS vaccine.
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to make generalizations about a single “rheumatic” HLA 
allele, and there are likely multiple HLA alleles that, in 
combination, increase an individual’s susceptibility to ARF 
and RHD. This is an area that needs continued research 
efforts to help target ARF prevention strategies to higher-
risk populations.
As discussed previously, the availability of a GABHS 
vaccine would be the best form of ARF prevention, espe-
cially since not all patients report upper respiratory infection 
symptoms or sore throat before their initial ARF occurrence. 
However, as shown in Figure 10, the M-types present in the 
26-valent GABHS vaccine being developed do not represent 
many of the M-types found in the developing world. Since 
we do not know all the possible “rheumatogenic” M-types, 
not vaccinating against prevalent M-types, such as 49, 58, 
and 81, may be missing the opportunity to prevent many 
cases of ARF, especially in developing nations where ARF 
and RHD are endemic. The vaccines that target the con-
served region of the M-protein are likely to provide better 
protection, but they are all currently in the experimental 
stage.68
Rheumatic fever remains a serious public health prob-
lem throughout the world. Despite our major advances 
in medical technology and understanding, we have not 
eradicated this disease. While a greater understanding of the 
detailed mechanisms of disease onset will advance scientific 
knowledge, it may not matter if one person is more suscep-
tible to developing chorea when exposed to streptococcal 
M-type 19 or another to developing carditis when exposed 
to streptococcal M-type 49; in the end, both will develop 
some form of ARF, and the common denominator is expo-
sure to GABHS. Preventing or providing early treatment for 
streptococcal infections will be the most important step to 
worldwide ARF eradication. It is hoped that presenting the 
continued worldwide problem of ARF and RHD will help 
promote further study into strategies to reduce the burden 
of this disease.
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